Evaluation of trilostane plus hydrocortisone in women with metastatic breast cancer and proir hormonal therapy exposure

J. N. Ingle, J. E. Krook, Daniel J Schaid, L. K. Everson, J. A. Mailliard, H. J. Long, G. W. McCormack

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Trilostane, which causes a perturbation of adrenal steroidogenesis, was studied in combination with hydrocortisone in 32 women with progressive metastatic breast cancer. Trilostane was administered orally at a dosage level of 240 mg four times daily after escalation over the first 10 days from 60 mg four times daily. Hydrocortisone was given orally at doses of 10mg at 8 a.m. and 5 p.m. and 20 mg at bedtime. Patients must have been postmenopausal (81%) or previously castrated (19%), had a response to the hormonal treatment just prior to study (81%) or a positive estrogen receptor at time of entry on study (41%), and a measurable indicator lesion. The number of prior hormonal therapies was 1 in 19 patients (59%), 2 in 12 patients (38%), and 3 in 1 patient (3%), respectively. Twelve patients (38%) achieved an objective response, and a 95% confidence interval for this results is from 21 to 56%. The median time to disease progression was 140 days, median duration of response was 278 days, and median survival was 556 days. Common toxicities included lethargy, lightheadedness, diarrhea, and abdominal discomfort. Eleven patients required a dosage reduction, usually because of gastrointestinal side effects, and one additional patient had the trilostane discontinued because of leukopenia. We conclude that the combination of trilostane plus hydrocortisone appears to have definite antitumor activity in women with metastatic breast cancer who have characteristics favorable for response to hormonal therapy.

Original languageEnglish (US)
Pages (from-to)93-97
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume13
Issue number2
StatePublished - 1990

Fingerprint

Implosive Therapy
Hydrocortisone
Breast Neoplasms
Lethargy
Leukopenia
Dizziness
trilostane
Estrogen Receptors
Disease Progression
Diarrhea
Therapeutics
Confidence Intervals
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Evaluation of trilostane plus hydrocortisone in women with metastatic breast cancer and proir hormonal therapy exposure. / Ingle, J. N.; Krook, J. E.; Schaid, Daniel J; Everson, L. K.; Mailliard, J. A.; Long, H. J.; McCormack, G. W.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 13, No. 2, 1990, p. 93-97.

Research output: Contribution to journalArticle

Ingle, J. N. ; Krook, J. E. ; Schaid, Daniel J ; Everson, L. K. ; Mailliard, J. A. ; Long, H. J. ; McCormack, G. W. / Evaluation of trilostane plus hydrocortisone in women with metastatic breast cancer and proir hormonal therapy exposure. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1990 ; Vol. 13, No. 2. pp. 93-97.
@article{d61385c418e748229403f8164ca538b9,
title = "Evaluation of trilostane plus hydrocortisone in women with metastatic breast cancer and proir hormonal therapy exposure",
abstract = "Trilostane, which causes a perturbation of adrenal steroidogenesis, was studied in combination with hydrocortisone in 32 women with progressive metastatic breast cancer. Trilostane was administered orally at a dosage level of 240 mg four times daily after escalation over the first 10 days from 60 mg four times daily. Hydrocortisone was given orally at doses of 10mg at 8 a.m. and 5 p.m. and 20 mg at bedtime. Patients must have been postmenopausal (81{\%}) or previously castrated (19{\%}), had a response to the hormonal treatment just prior to study (81{\%}) or a positive estrogen receptor at time of entry on study (41{\%}), and a measurable indicator lesion. The number of prior hormonal therapies was 1 in 19 patients (59{\%}), 2 in 12 patients (38{\%}), and 3 in 1 patient (3{\%}), respectively. Twelve patients (38{\%}) achieved an objective response, and a 95{\%} confidence interval for this results is from 21 to 56{\%}. The median time to disease progression was 140 days, median duration of response was 278 days, and median survival was 556 days. Common toxicities included lethargy, lightheadedness, diarrhea, and abdominal discomfort. Eleven patients required a dosage reduction, usually because of gastrointestinal side effects, and one additional patient had the trilostane discontinued because of leukopenia. We conclude that the combination of trilostane plus hydrocortisone appears to have definite antitumor activity in women with metastatic breast cancer who have characteristics favorable for response to hormonal therapy.",
author = "Ingle, {J. N.} and Krook, {J. E.} and Schaid, {Daniel J} and Everson, {L. K.} and Mailliard, {J. A.} and Long, {H. J.} and McCormack, {G. W.}",
year = "1990",
language = "English (US)",
volume = "13",
pages = "93--97",
journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Evaluation of trilostane plus hydrocortisone in women with metastatic breast cancer and proir hormonal therapy exposure

AU - Ingle, J. N.

AU - Krook, J. E.

AU - Schaid, Daniel J

AU - Everson, L. K.

AU - Mailliard, J. A.

AU - Long, H. J.

AU - McCormack, G. W.

PY - 1990

Y1 - 1990

N2 - Trilostane, which causes a perturbation of adrenal steroidogenesis, was studied in combination with hydrocortisone in 32 women with progressive metastatic breast cancer. Trilostane was administered orally at a dosage level of 240 mg four times daily after escalation over the first 10 days from 60 mg four times daily. Hydrocortisone was given orally at doses of 10mg at 8 a.m. and 5 p.m. and 20 mg at bedtime. Patients must have been postmenopausal (81%) or previously castrated (19%), had a response to the hormonal treatment just prior to study (81%) or a positive estrogen receptor at time of entry on study (41%), and a measurable indicator lesion. The number of prior hormonal therapies was 1 in 19 patients (59%), 2 in 12 patients (38%), and 3 in 1 patient (3%), respectively. Twelve patients (38%) achieved an objective response, and a 95% confidence interval for this results is from 21 to 56%. The median time to disease progression was 140 days, median duration of response was 278 days, and median survival was 556 days. Common toxicities included lethargy, lightheadedness, diarrhea, and abdominal discomfort. Eleven patients required a dosage reduction, usually because of gastrointestinal side effects, and one additional patient had the trilostane discontinued because of leukopenia. We conclude that the combination of trilostane plus hydrocortisone appears to have definite antitumor activity in women with metastatic breast cancer who have characteristics favorable for response to hormonal therapy.

AB - Trilostane, which causes a perturbation of adrenal steroidogenesis, was studied in combination with hydrocortisone in 32 women with progressive metastatic breast cancer. Trilostane was administered orally at a dosage level of 240 mg four times daily after escalation over the first 10 days from 60 mg four times daily. Hydrocortisone was given orally at doses of 10mg at 8 a.m. and 5 p.m. and 20 mg at bedtime. Patients must have been postmenopausal (81%) or previously castrated (19%), had a response to the hormonal treatment just prior to study (81%) or a positive estrogen receptor at time of entry on study (41%), and a measurable indicator lesion. The number of prior hormonal therapies was 1 in 19 patients (59%), 2 in 12 patients (38%), and 3 in 1 patient (3%), respectively. Twelve patients (38%) achieved an objective response, and a 95% confidence interval for this results is from 21 to 56%. The median time to disease progression was 140 days, median duration of response was 278 days, and median survival was 556 days. Common toxicities included lethargy, lightheadedness, diarrhea, and abdominal discomfort. Eleven patients required a dosage reduction, usually because of gastrointestinal side effects, and one additional patient had the trilostane discontinued because of leukopenia. We conclude that the combination of trilostane plus hydrocortisone appears to have definite antitumor activity in women with metastatic breast cancer who have characteristics favorable for response to hormonal therapy.

UR - http://www.scopus.com/inward/record.url?scp=0025359386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025359386&partnerID=8YFLogxK

M3 - Article

C2 - 2316487

AN - SCOPUS:0025359386

VL - 13

SP - 93

EP - 97

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

SN - 0277-3732

IS - 2

ER -